<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AZELEX - azelaic acid cream </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>AZELEX® <br>(azelaic acid cream) 20% <br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">For Dermatologic Use Only <br>Not for Ophthalmic Use
</span><br></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">AZELEX<span class="Sup">®</span> (azelaic acid cream) 20% contains azelaic acid, a naturally occurring saturated dicarboxylic acid.
</p>
<p>Structural Formula: HOOC-(CH<span class="Sub">2</span>)<span class="Sub">7</span>-COOH
</p>
<p>Chemical Name: 1,7-heptanedicarboxylic acid
</p>
<p>Empirical Formula: C<span class="Sub">9</span>H<span class="Sub">16</span>O<span class="Sub">4</span></p>
<p>Molecular Weight: 188.22
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold">Active Ingredient:</span> Each gram of AZELEX<span class="Sup">®</span> contains azelaic acid......... 0.2 gm (20% w/w).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<p class="First"><span class="Bold">Inactive Ingredients:</span> cetearyl octanoate; glycerin; glyceryl stearate and cetearyl alcohol and cetyl palmitate and cocoglycerides; PEG-5 glyceryl stearate; propylene glycol; and purified water. Benzoic acid is present as a preservative.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">The exact mechanism of action of azelaic acid is not known. The following <span class="Italics">in vitro</span> data are available, but their clinical significance is unknown. Azelaic acid has been shown to possess antimicrobial activity against <span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span> and Staphylococcus epidermidis.</span> The antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis.
</p>
<p>A normalization of keratinization leading to an anticomedonal effect of azelaic acid may also contribute to its clinical activity. Electron microscopic and immunohistochemical evaluation of skin biopsies from human subjects treated with AZELEX<span class="Sup">®</span> Cream demonstrated a reduction in the thickness of the stratum corneum, a reduction in number and size of keratohyalin granules, and a reduction in the amount and distribution of filaggrin (a protein component of keratohyalin) in epidermal layers. This is suggestive of the ability to decrease microcomedo formation.
</p>
<div class="Section" data-sectionCode="43682-4">
<a name="s6"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics:</span> Following a single application of AZELEX<span class="Sup">®</span> Cream to human skin <span class="Italics">in vitro</span>, azelaic acid penetrates into the stratum corneum (approximately 3 to 5% of the applied dose) and other viable skin layers (up to 10% of the dose is found in the epidermis and dermis). Negligible cutaneous metabolism occurs after topical application. Approximately 4% of the topically applied azelaic acid is systemically absorbed. Azelaic acid is mainly excreted unchanged in the urine but undergoes some β-oxidation to shorter chain dicarboxylic acids. The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.
</p>
<p>Azelaic acid is a dietary constituent (whole grain cereals and animal products), and can be formed endogenously from longer-chain dicarboxylic acids, metabolism of oleic acid, and ψ-oxidation of monocarboxylic acids. Endogenous plasma concentration (20 to 80 ng/mL) and daily urinary excretion (4 to 28 mg) of azelaic acid are highly dependent on dietary intake. After topical treatment with AZELEX<span class="Sup">®</span> Cream in humans, plasma concentration and urinary excretion of azelaic acid are not significantly different from baseline levels.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">AZELEX<span class="Sup">®</span> Cream is indicated for the topical treatment of mild-to-moderate inflammatory <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">AZELEX<span class="Sup">®</span> Cream is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">AZELEX<span class="Sup">®</span> Cream is for dermatologic use only and not for ophthalmic use.
</p>
<p>There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexions, these patients should be monitored for early signs of hypopigmentation.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s10"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s11"></a><a name="section-7.1"></a><p></p>
<h2>General:
</h2>
<p class="First">If sensitivity or severe irritation develop with the use of AZELEX<span class="Sup">®</span> Cream, treatment should be discontinued and appropriate therapy instituted.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s12"></a><a name="section-7.2"></a><p></p>
<h2>Information for patients:
</h2>
<p class="First">Patients should be told:
</p>
<ol class="Arabic">
<li>To use AZELEX<span class="Sup">®</span> Cream for the full prescribed treatment period.
</li>
<li> To avoid the use of occlusive dressings or wrappings.
</li>
<li> To keep AZELEX<span class="Sup">®</span> Cream away from the mouth, eyes and other mucous membranes. If it does come in contact with the eyes, they should wash their eyes with large amounts of water and consult a physician if <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span> persists.
</li>
<li> If they have dark complexions, to report abnormal changes in skin color to their physician.
</li>
<li> Due in part to the low pH of azelaic acid, temporary <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span> (<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, burning, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>) may occur when AZELEX<span class="Sup">®</span>
Cream is applied to broken or inflamed skin, usually at the start of treatment. However, this irritation commonly subsides if treatment is continued. If it continues, AZELEX<span class="Sup">®</span>
Cream should be applied only once-a-day, or the treatment should be stopped until these effects have subsided. If troublesome irritation persists, use should be discontinued, and patients should consult their physician. 
</li>
</ol>(See <a href="#s19">ADVERSE REACTIONS.)</a>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s13"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility:
</h2>
<p class="First">Azelaic acid is a human dietary component of a simple molecular structure that does not suggest carcinogenic potential, and it does not belong to a class of drugs for which there is a concern about carcinogenicity. Therefore, animal studies to evaluate carcinogenic potential with AZELEX<span class="Sup">®</span> Cream were not deemed necessary. In a battery of tests (Ames assay, HGPRT test in Chinese hamster ovary cells, human lymphocyte test, dominant lethal assay in mice), azelaic acid was found to be nonmutagenic. Animal studies have shown no adverse effects on fertility.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s14"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy:
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s15"></a><a name="section-7.4.1"></a><p></p>
<h3>Teratogenic Effects: Pregnancy Category B.
</h3>
<p class="First">Embryotoxic effects were observed in Segment I and Segment II oral studies with rats receiving 2500 mg/kg/day of azelaic acid. Similar effects were observed in Segment II studies in rabbits given 150 to 500 mg/kg/day and in monkeys given 500 mg/kg/day. The doses at which these effects were noted were all within toxic dose ranges for the dams. No teratogenic effects were observed. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s16"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers:
</h2>
<p class="First">Equilibrium dialysis was used to assess human milk partitioning <span class="Italics">in vitro.</span> At an azelaic acid concentration of 25 μg/mL, the milk/plasma distribution coefficient was 0.7 and the milk/buffer distribution was 1.0, indicating that passage of drug into maternal milk may occur. Since less than 4% of a topically applied dose is systemically absorbed, the uptake of azelaic acid into maternal milk is not expected to cause a significant change from baseline azelaic acid levels in the milk. However, caution should be exercised when AZELEX<span class="Sup">®</span> Cream is administered to a nursing mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s17"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use:
</h2>
<p class="First">Safety and effectiveness in pediatric patients under 12 years of age have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s18"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use:
</h2>
<p class="First">Clinical studies of AZELEX<span class="Sup">®</span> Cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s19"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">During U.S. clinical trials with AZELEX<span class="Sup">®</span>Cream, adverse reactions were generally mild and transient in nature. The most common adverse reactions occurring in approximately 1-5% of patients were <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>. Other adverse reactions such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, dryness, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, irritation, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> were reported in less than 1% of subjects. There is the potential for experiencing <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> with use of AZELEX<span class="Sup">®</span>Cream.
</p>
<p>In patients using azelaic acid formulations, the following additional adverse experiences have been reported rarely: worsening of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="138502" conceptname="Vitiligo">vitiligo</span> depigmentation, small depigmented spots, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, reddening (signs of <span class="product-label-link" type="condition" conceptid="4197127" conceptname="Keratosis pilaris">keratosis pilaris</span>), and exacerbation of recurrent <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s20"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">After the skin is thoroughly washed and patted dry, a thin film of AZELEX<span class="Sup">®</span> Cream should be gently but thoroughly massaged into the affected areas twice daily, in the morning and evening. The hands should be washed following application. The duration of use of AZELEX<span class="Sup">®</span> Cream can vary from person to person and depends on the severity of the <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. Improvement of the condition occurs in the majority of patients with inflammatory lesions within four weeks.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s21"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">AZELEX<span class="Sup">®</span> Cream is supplied in a closed orifice tube with a white, spiked screwcap in the following sizes:
</p>
<p>30 g - NDC 54868-4442-0<br><br></p>
<p><span class="Bold">Note:</span> Protect from freezing. Store product on its side.
</p>
<p>Store between 15° - 30° C (59° - 86° F).
</p>
<p><span class="Bold">Rx Only.</span></p>
<p>Distributed by:
						</p>
<p><img alt="Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d5269d5-6555-4d2c-bc3b-df862b014275&amp;name=aze00-0000-01.jpg"></p>
<p>Irvine, California 92612, U.S.A.
</p>
<p>©2004 Allergan, Inc.
</p>
<p>Made in Italy
</p>
<p>8466X
</p>
<p>Distributed under license.
</p>
<p><span class="Sup">®</span> Mark of Allergan, Inc.
</p>
<p>Revised May 2004
</p>
<p>70896US15P</p>
<br><p><br></p>
<p><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma        74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s22"></a><a name="section-11"></a><p></p>
<p class="First">NDC 54868-4442-0</p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d5269d5-6555-4d2c-bc3b-df862b014275&amp;name=4442.jpg"></p>
<p></p>
<p><span class="Bold">AZELEX</span><span class="Sup">®</span></p>
<p><span class="Bold">(azelaic acid cream) 20%</span></p>
<p>For Dermatologic Use Only
</p>
<p>Not for Ophthalmic Use
</p>
<p><span class="Bold">Rx Only</span>          <br></p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AZELEX 		
					</strong><br><span class="contentTableReg">azelaic acid cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4442(NDC:0023-8694)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">CUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>azelaic acid</strong> (azelaic acid) </td>
<td class="formItem">azelaic acid</td>
<td class="formItem">0.2 g  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cetearyl ethylhexanoate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cetostearyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cetyl palmitate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glyceryl monostearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>coco-glycerides</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glyceryl monostearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzoic acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4442-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020428</td>
<td class="formItem">05/31/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0a0a3e7e-68d9-4201-bd3d-4fe0d7caf35b</div>
<div>Set id: 0d5269d5-6555-4d2c-bc3b-df862b014275</div>
<div>Version: 1</div>
<div>Effective Time: 20120611</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
